ABSTRACT
Uroacitide is a new anti-tumor drug, which is extracted from non-cytotoxic urine of the healthy human urine. In recent years, there have been many basic experiments and clinical trials focusing on its role in hematological diseases, especially in the treatment of myelodysplastic syndromes (MDS). There are also some basic researches on the treatment of other hematological diseases, which lays a foundation for further expanding its clinical indications and opens up a new way for the treatment of hematological diseases.
ABSTRACT
Uroacitide is a new anti-tumor drug, which is extracted from non-cytotoxic urine of the healthy human urine. In recent years, there have been many basic experiments and clinical trials focusing on its role in hematological diseases, especially in the treatment of myelodysplastic syndromes (MDS). There are also some basic researches on the treatment of other hematological diseases, which lays a foundation for further expanding its clinical indications and opens up a new way for the treatment of hematological diseases.
ABSTRACT
Eltrombopag is a kind of human thrombopoietin receptor agonist, which is used to treat thrombocytopenia and severe aplastic anemia. In recent years, it highlights the huge advantage in iron removal. It regulates the acidification of glucuronidation in the body, removing it from feces and urine before iron conjugates to the liver, so as to effectively reduce the overload of iron in the body.